908 Devices Inc. Common Stock Canaccord Genuity's 46th Annual Growth Conference

Yeah, absolutely. Thanks so much for hosting us here today, Austin. I really appreciate the opportunity. Yeah, so 908 Devices is creating a category of handheld detection solutions aimed at public safety and defense customers, really geared towards chemical detection and drug detection applications specifically. The fentanyl crisis, nitazenes, xylazine, other compounds of the synthetic opioids, as well as toxic industrial chemicals, and having a complete suite of handheld devices to address those applications. From a medical device, as you put it, so 908 really is coming back to our roots a little bit here. When we started the company in 2012, we built a handheld mass spectrometry technology, which is taking a lab-grade technology of mass spectrometry and taking it out of the lab and bringing it to the user that could have access at the point of need for immediate answers.

The pinnacle of that to us was a battery-powered smallest that we could do at the time and developing a solution that didn't exist, new category, and we did so with purpose-built for military and security applications. Now you fast-forward, that mass spectrometry is a platform, and we continue to look through applied areas and markets as well as into life sciences. When Austin's mentioning the medical devices, when we were at the throes of our IPO in 2020, we really were gearing up and launching products into the bioprocessing, biopharma space. About 15 months ago, we've divested that business line, and now we're fully focused on the category of defining handheld detection for these public health, safety, and defense markets.

In many ways, coming back to our roots, an area that we know well, and an area that we've seen a lot of strong growth over those years.